Advertisement
U.S. markets close in 3 hours 9 minutes
  • S&P 500

    5,251.84
    +3.35 (+0.06%)
     
  • Dow 30

    39,769.65
    +9.57 (+0.02%)
     
  • Nasdaq

    16,383.80
    -15.73 (-0.10%)
     
  • Russell 2000

    2,130.40
    +16.05 (+0.76%)
     
  • Crude Oil

    82.84
    +1.49 (+1.83%)
     
  • Gold

    2,245.90
    +33.20 (+1.50%)
     
  • Silver

    25.02
    +0.27 (+1.10%)
     
  • EUR/USD

    1.0807
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • GBP/USD

    1.2644
    +0.0006 (+0.05%)
     
  • USD/JPY

    151.2800
    +0.0340 (+0.02%)
     
  • Bitcoin USD

    70,828.29
    +1,701.02 (+2.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

MA-based Boston Scientific Corporation BSX is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg.

Currently, Boston Scientific has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:

Earnings: The Zacks Consensus Estimate remained steady at 34 cents per share over the last 30 days. Boston Scientific’s adjusted earnings of 34 cents per share is in line with the Zacks Consensus Estimate.

Boston Scientific Corporation Price and EPS Surprise

Boston Scientific Corporation Price and EPS Surprise | Boston Scientific Corporation Quote

 

Revenues: Boston Scientific posted revenues of $2.41 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.38 billion.

Key Stats: In the fourth-quarter 2017, Boston Scientific’s Cardiovascular segment revenues increased 6.8% to $913 million, while rhythm management segment’s revenue grew 3.2%, totaling $565 million. Also, revenues from the MedSurg segment improved 12.8% to $931 million.

Major Factors: Boston Scientific has posted impressive fourth quarter results by delivering revenue growth across all segments. Moreover, the company received FDA approval of the Vercise Deep Brain Stimulation (DBS) System to treat the symptoms of Parkinson's disease. Also, the company has won FDA approval for the Spectra WaveWriter Spinal Cord Stimulator System. The company has also issued guidance for first quarter 2018 and full-year 2018 guidance.

Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.

Check back later for our full write up on this Boston Scientific earnings report later!

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement